miRecule
Gaithersburg, US · Founded 2018 · Delaware corporation · 6 known investors
Find your way into miRecule
176 people in our graph share verified history with the miRecule team — schools, employers, funds. One of them is your warm intro.
Daniel Jacobsunlockedknows Dave Lemus · together at miRecule (overlapped)
knows the team · via Silence Therapeutics plc
knows the team · via MIMETAS
×8knows the team · via BioHealth Innovation, Inc.
knows the team · via National Institutes of Health (NIH): Intramural Research Program (IRP)
miRecule is a biotechnology company developing therapeutics, with programs focused on oncology. It applies RNA-based drug development approaches within the biotech industry.
Founders & leadership
miRecule was founded in 2018 by Anthony D. Saleh, Ph.D..
AD
Anthony D. Saleh, Ph.D.Co-founder and CEOBefore co-founding miRecule in 2018, Saleh served as Entrepreneur in Residence at BioHealth Innovation and as President of MIMETAS US and Director of Product R&D at MIMETAS BV. His research career includes postdoctoral fellowships at the National Cancer Institute and NIDCD, followed by work as a scientist in the Tumor Biology Section of the NIH Intramural Research Program.
AD
DL
Dave LemusCOO/CFOHe has held C-level executive roles in US and European pharmaceutical and biotech companies, with experience in R&D organizations and specialty pharma, and has served as a non-executive board director for multiple public and private companies.
Investors · 6
Boutique Venture PartnersPalo Alto
Brown and White VenturesFairport
Pathway BioventuresChicago
Tachyon VenturesLos Angeles
AlexandriareportedPasadena
Also in the syndicate · 1
SOLVE FSHD
Reported raises · per SEC filings
Form D private placements$1.5M disclosed across 1 of 3 rounds · 2019–2022
▶$1.5MraisedNov 2019 · 3 investors · BiotechnologyRule 506(b)
▶$1.5MraisedNov 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony SalehExecutive Officer
- Offering amount
- $2.3M
- Amount sold
- $1.5M
- Minimum investment
- $100K
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Uniqure6 shared keywordsuniQure is a biotech company developing gene therapies for serious genetic diseases. The company's pipeline includes investigational treatments for conditions such as Huntington's disease, epilepsy, and Fabry disease.
Doximity5 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Iecure5 shared keywordsiECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children. Its initial focus is on neurometabolic and urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency.
Emolecules5 shared keywordseMolecules operates a digital chemical search platform and procurement service connecting researchers to over 83 million available chemical compounds from a global supplier network. The company serves drug discovery researchers and biopharmaceutical organizations seeking to reduce timelines and improve efficiencies in early-stage compound acquisition and management.
Companies competing with miRecule for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $739.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $305K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $410.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does miRecule do?
- miRecule is a biotechnology company developing therapeutics, with programs focused on oncology. It applies RNA-based drug development approaches within the biotech industry.
- Who founded miRecule?
- miRecule was founded by Anthony D. Saleh, Ph.D. in 2018.
- Who are miRecule's investors?
- miRecule's investors include Boutique Venture Partners, Brown and White Ventures, Pathway Bioventures, Tachyon Ventures, Alexandria.
- How much funding has miRecule raised?
- miRecule has disclosed $1.5M raised across 1 of its 3 known rounds.
- Where is miRecule headquartered?
- miRecule is headquartered in Gaithersburg, US.